Drugs / RSV604
RSV604
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00416442 | Oct → Nov 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00232635 | Sep 2005 → Jul 2006 | respiratory syncytial virus infectious disease | Arrow Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00416442 ↗ |
| Known as | A-60444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00232635 ↗ |
| Known as | RSV604A | ChEMBL registry synonym — accepted as the source's own label CHEMBL223402 ↗ |
| Modality | Small molecule | — CHEMBL223402 ↗ |
| Route | Oral | “exposure and safety of oral A-60444 in post-stem cell transplant patients with RSV infection” NCT00232635 ↗ |